Mutational Analysis of the P53 and K-ras Genes and Allelotype Study of the Rb-1 Gene for Investigating the Pathogenesis of Combined Hapatocellular-cholangiocellular Carcinomas

Overview

Journal Jpn J Cancer Res

Specialty Oncology

Date 1996 Oct 1

PMID 8957064

Citations 13

Authors

Y Imai

H Oda

M Arai

S Shimizu

Y Nakatsuru

T Inoue

T Ishikawa

Affiliations

Soon will be listed here.

Abstract

Because combined hepatocellular-cholangiocellular carcinoma is rare and its biological features and pathogenesis have not been well established, we investigated alterations of the p53, K-ras and Rb-1 genes, as well as expression patterns of carcinoembryonic antigen and keratin, in seven combined hepatocellular-cholangiocarcinomas out of 557 hepatocellular carcinomas autopsied at Tokyo University during 30 years. Mutations of the p53 gene were found in two cases, at codon 244 (GGC to TGC) in the cholangiocellular carcinoma component of case 1 (mixed type, showing an intimate intermingling of both elements) and at codon 234 (TAC to AAC) in both components of case 5 (combined type, consisting of contiguous but independent masses of both elements). Mutation of the K-ras gene (codon 12, GGT to GAT) was seen only in the cholangiocellular carcinoma component of clinically apparent double cancer, case 6. Allelic alteration of the Rb-1 gene was observed in two cases, deletion of both alleles in the hepatocellular carcinoma component of case 3 (combined type) and replication error of the same pattern in both components of case 4 (mixed type). Immunohistochemical analysis showed that the hepatocellular carcinoma components of five cases (cases 2, 3, 5, 6, 7) were immunoreactive for keratin, suggesting biliary epithelial transformation. In four of the five cases (cases 3 and 5 combined, case 7 mixed and case 6 double cancer), cholangiocellular carcinoma components were also positive for keratin. These results suggest that both components of combined hepatocellular-cholangiocarcinoma have the same genetic and phenotypic character and might have arisen from the same origin in some cases.

Citing Articles

Combined hepatocellular-cholangiocarcinoma: a population level analysis of incidence and mortality trends.

Wang J, Li E, Yang H, Wu J, Lu H, Yi C World J Surg Oncol. 2019; 17(1):43.

PMID: 30813932 PMC: 6394104. DOI: 10.1186/s12957-019-1586-8.

A genetic database can be utilized to identify potential biomarkers for biphenotypic hepatocellular carcinoma-cholangiocarcinoma.

Mok S, Mohan S, Grewal N, Elfant A, Judge T J Gastrointest Oncol. 2016; 7(4):570-9.

PMID: 27563447 PMC: 4963376. DOI: 10.21037/jgo.2016.04.01.

Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Wang A, Zheng Y, Du J, Zhu C, Huang H, Wang S World J Gastroenterol. 2016; 22(18):4459-65.

PMID: 27182157 PMC: 4858629. DOI: 10.3748/wjg.v22.i18.4459.

Genetic profiling of intrahepatic cholangiocarcinoma.

Andersen J, Thorgeirsson S Curr Opin Gastroenterol. 2012; 28(3):266-72.

PMID: 22395571 PMC: 4017233. DOI: 10.1097/MOG.0b013e3283523c7e.

Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis.

Watanabe T, Sakata J, Ishikawa T, Shirai Y, Suda T, Hirono H World J Hepatol. 2010; 1(1):103-9.

PMID: 21160972 PMC: 2998951. DOI: 10.4254/wjh.v1.i1.103.

References

Hsu H, Chiou T, Chen J, Lee C, Lee P, Peng S . Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology. 1991; 13(5):923-8. View

Hsu I, Metcalf R, Sun T, Welsh J, Wang N, Harris C . Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350(6317):427-8. DOI: 10.1038/350427a0. View

Aoki K, Takayasu K, Kawano T, Muramatsu Y, Moriyama N, Wakao F . Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features and computed tomographic findings. Hepatology. 1993; 18(5):1090-5. View

Hsu S, RAINE L, FANGER H . Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981; 29(4):577-80. DOI: 10.1177/29.4.6166661. View

Nishida N, Fukuda Y, Kokuryu H, Sadamoto T, Isowa G, Honda K . Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma. Int J Cancer. 1992; 51(6):862-8. DOI: 10.1002/ijc.2910510605. View

Walker G, Hayward N, Falvey S, Cooksley W . Loss of somatic heterozygosity in hepatocellular carcinoma. Cancer Res. 1991; 51(16):4367-70. View

Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S . Cholangiocarcinomas in Japanese and Thai patients: difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog. 1992; 6(4):266-9. DOI: 10.1002/mc.2940060408. View

McGrath J, Capon D, Smith D, Chen E, Seeburg P, Goeddel D . Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature. 1983; 304(5926):501-6. DOI: 10.1038/304501a0. View

Allen R, LISA J . Combined liver cell and bile duct carcinoma. Am J Pathol. 1949; 25(4):647-55. PMC: 1942823. View

10.

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

11.

Goodman Z, Ishak K, Langloss J, Sesterhenn I, Rabin L . Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985; 55(1):124-35. DOI: 10.1002/1097-0142(19850101)55:1<124::aid-cncr2820550120>3.0.co;2-z. View

12.

Impraim C, Saiki R, Erlich H, TEPLITZ R . Analysis of DNA extracted from formalin-fixed, paraffin-embedded tissues by enzymatic amplification and hybridization with sequence-specific oligonucleotides. Biochem Biophys Res Commun. 1987; 142(3):710-6. DOI: 10.1016/0006-291x(87)91472-0. View

13.

Van Eyken P, Sciot R, Paterson A, Callea F, Kew M, Desmet V . Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1988; 19(5):562-8. DOI: 10.1016/s0046-8177(88)80205-3. View

14.

Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S . Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res. 1992; 52(13):3674-8. View

15.

Call K, Glaser T, Ito C, Buckler A, Pelletier J, Haber D . Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990; 60(3):509-20. DOI: 10.1016/0092-8674(90)90601-a. View

16.

Zhang X, Xu H, Murakami Y, Sachse R, Yashima K, Hirohashi S . Deletions of chromosome 13q, mutations in Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. Cancer Res. 1994; 54(15):4177-82. View

17.

Fisher H, Doppl W, Osborn M, Altmannsberger M . Evidence for a hepatocellular lineage in a combined hepatocellular-cholangiocarcinoma of transitional type. Virchows Arch B Cell Pathol Incl Mol Pathol. 1988; 56(2):71-6. DOI: 10.1007/BF02890004. View

18.

Tada M, Omata M, OHTO M . Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res. 1990; 50(4):1121-4. View

19.

Murakami Y, Hayashi K, Hirohashi S, Sekiya T . Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 1991; 51(20):5520-5. View

20.

Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y . Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterology. 1995; 109(5):1612-7. DOI: 10.1016/0016-5085(95)90650-9. View